Qiagen stock: analysis & valuation

QIA.DEDiagnostics & ResearchNetherlandsData as of Nov 15, 2026
Metrics analysis · Diagnostics & Research

Qiagen QIA.DE

Price 45.30 EUR +0.13%Market cap 9.4 bn EUR52 weeks 27.56 – 47.59
Forward P/E
19.6x
Industry 26.0x
EV/EBITDA
14.8x
Industry 21.2x
Revenue growth
2.9%
Industry 8.5%
Operating margin
26.7%
Industry 16.0%
Return on equity
10.8%
Industry 10.8%
Free cash flow yield
3.6%
Industry 2.7%

What does Qiagen do?

Qiagen is a company specializing in molecular diagnostics and life science research, headquartered in the Netherlands. It provides solutions that turn biological samples into usable molecular insights. These include consumables for the stabilization and purification of nucleic acids, instruments for sample preparation and quality control, as well as test systems and analysis software.

Qiagen generates most of its revenue from recurring consumables used on installed instruments. Its customers are hospitals, laboratories, pharmaceutical and biotechnology companies, and academic research institutions. Important fields of application include tests of immune response, for example to tuberculosis, monitoring of viral infections after transplants, oncology, and tests in reproductive and sexual health. Competitively, Qiagen is regarded as an established provider of sample preparation. Its competitors range from large diagnostics and life science groups to specialized providers. Differentiation comes from the installed instrument base, market approvals and partnerships with pharmaceutical companies.

Score profile

Quality7.4
Valuation6.8
Growth1.0
Financial strength7.1
Momentum9.3

Rank vs. Diagnostics & Research (25 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Qiagen ranks above average in the group Diagnostics & Research (7.4/10). On growth, the company ranks in the bottom fifth in the group Diagnostics & Research (1.0/10). On valuation (higher = cheaper), the stock ranks above average in the group Diagnostics & Research (6.8/10). On financial strength, Qiagen ranks above average in the group Diagnostics & Research (7.1/10).

MetricStockGroup medianRanking
Forward P/E19.6x26.0xbetter than 80 %
Trailing P/E28.5x36.2xbetter than 73 %
PEG ratio1.3x1.7xbetter than 63 %
EV/EBITDA14.8x21.2xbetter than 80 %
Price/sales4.9x4.9xbetter than 50 %
Price/book3.0x4.9xbetter than 69 %
Revenue growth2.9%8.5%better than 10 %
Earnings growth-19.2%16.3%better than 10 %
Gross margin67.0%54.6%better than 86 %
Operating margin26.7%16.0%better than 86 %
Net margin18.2%9.5%better than 74 %
Return on equity10.8%10.8%better than 50 %
Debt/equity47.4%54.1%better than 65 %
Current ratio2.6x1.9xbetter than 70 %
Free cash flow yield3.6%2.7%better than 78 %
Dividend yield0.7%0.8%–
Payout ratio19.0%24.4%–
Beta0.561.17–

Valuation: what is Qiagen worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Qiagen a model range of 28.40 EUR to 66.48 EUR per share.

Price 45.30 EUR
Analysts 43.10 EUR
Fair value range 28.40 EUR – 66.48 EURMidpoint 45.92 EUR (+1.4% vs. price)

5 analysts, average rating “Hold”, average price target 43.10 EUR (−4.9%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Recurring consumables on an installed instrument base provide predictable revenue and tie customers to the platforms over the long term.
  • Demand for molecular diagnostics, for example in oncology and infectious diseases, rises with the spread of personalized medicine.
  • Partnerships with pharmaceutical companies for companion diagnostics open up additional applications and strengthen the position in oncology.

Risks

  • Regulatory approvals and reimbursement decisions can delay market launches and affect the profitability of new tests.
  • Competitors with greater resources and competing technologies can gain market share and create price pressure.
  • Fluctuating research budgets and investment by pharmaceutical and academic customers, as well as currency effects, weigh on business performance.

What to look for with Qiagen

The share of recurring consumables revenue in total revenue is informative because it reflects the stability and predictability of the platform-based business model.

Full AI analysis of Qiagen

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Qiagen stock

What is the P/E ratio of Qiagen stock?

Based on expected earnings, Qiagen trades at a P/E of 19.6x, compared with a median of 26.0x for the peer group Diagnostics & Research. Based on the earnings of the last twelve months it is 28.5x. (data as of Nov 15, 2026)

Does Qiagen pay a dividend?

Yes. The dividend yield is currently 0.7%, with a payout ratio of 19.0% of earnings.

Is Qiagen stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Qiagen is currently valued cheaper than most companies in the group Diagnostics & Research (valuation score 6.8 out of 10). Our model calculations (DCF and industry multiples) give a range of 28.40 EUR to 66.48 EUR per share at a price of 45.30 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Qiagen stock?

5 analysts have an average price target of 43.10 EUR (−4.9% vs. the current price); the average rating is “Hold”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.